Type 2 deiodinase at the crossroads of thyroid hormone action

被引:68
作者
Arrojo e Drigo, Rafael [1 ]
Bianco, Antonio C. [1 ]
机构
[1] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA
关键词
Deiodinase; Metabolism; Ubiquitination; Dimerization; ENDOPLASMIC-RETICULUM STRESS; I IODOTHYRONINE DEIODINASE; CONJUGATING ENZYME UBC7; LINDAU TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; ER STRESS; SUBCELLULAR-LOCALIZATION; ADAPTIVE THERMOGENESIS; THR92ALA POLYMORPHISM; TARGETED DISRUPTION;
D O I
10.1016/j.biocel.2011.05.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thyroid hormone action can be customized on a cell-specific fashion through the controlled action of the deiodinase group of enzymes, which are homodimeric thioredoxin fold containing selenoproteins. Whereas the type II deiodinase (D2) initiates thyroid hormone signaling by activating the pro-hormone thyroxine (T4) to the biologically active T3 molecule, the type III deiodinase (D3) terminates thyroid hormone action by catalyzing the inactivation of both T4 and T3 molecules. Deiodinases play a role in thyroid hormone homeostasis, development, growth and metabolic control by affecting the intracellular levels of T3 and thus gene expression on a cell-specific basis. Whereas both Dio2 and Dio3 are transcriptionally regulated, ubiquitination of D2 is a switch mechanism that controls D2 activity and intracellular 13 production. The hedgehog-inducible WSB-1 and the yeast Doa10 mammalian ortholog TEB4 are two E3 ligases that inactivate D2 via ubiquitination. Inactivation involves disruption of the D2:D2 dimer and can be reversed via two ubiquitin-specific proteases, USP20 and USP33, rescuing catalytic activity and T3 production. The ubiquitin-based switch mechanism that controls D2 activity illustrates how different cell types fine-tune thyroid hormone signaling, making D2 a suitable target for pharmacological intervention. This article reviews the cellular and molecular aspects of D2 regulation and the current models of D2-mediated thyroid hormone signaling. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1432 / 1441
页数:10
相关论文
共 114 条
  • [91] Targeted disruption of the type 2 selenodeiodinase gene (D102) results in a phenotype of pituitary resistance to T4
    Schneider, MJ
    Fiering, SN
    Pallud, SE
    Parlow, AF
    St Germain, DL
    Galton, VA
    [J]. MOLECULAR ENDOCRINOLOGY, 2001, 15 (12) : 2137 - 2148
  • [92] Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice
    Schneider, MJ
    Fiering, SN
    Thai, B
    Wu, SY
    St Germain, E
    Parlow, AF
    St Germain, DL
    Galton, VA
    [J]. ENDOCRINOLOGY, 2006, 147 (01) : 580 - 589
  • [93] Endoplasmic reticulum stress responses
    Schroeder, M.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (06) : 862 - 894
  • [94] Schroeder M, 2010, METHODS MOL BIOL, V648, P43, DOI 10.1007/978-1-60761-756-3_3
  • [95] Silva J Enrique, 2011, Front Biosci (Schol Ed), V3, P352, DOI 10.2741/s156
  • [96] On vesicle formation and tethering in the ER-Golgi shuttle
    Spang, Anne
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (04) : 531 - 536
  • [97] Insights into the role of deiodinases from studies of genetically modified animals
    St Germain, DL
    Hernandez, A
    Schneider, MJ
    Galton, VA
    [J]. THYROID, 2005, 15 (08) : 905 - 916
  • [98] Minireview: Defining the Roles of the Iodothyronine Deiodinases: Current Concepts and Challenges
    St Germain, Donald L.
    Galton, Valerie Anne
    Hernandez, Arturo
    [J]. ENDOCRINOLOGY, 2009, 150 (03) : 1097 - 1107
  • [99] Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center
    Steinsapir, J
    Bianco, AC
    Buettner, C
    Harney, J
    Larsen, PR
    [J]. ENDOCRINOLOGY, 2000, 141 (03) : 1127 - 1135
  • [100] Type 2 lodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes
    Steinsapir, J
    Harney, J
    Larsen, PR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (11) : 1895 - 1899